Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

SHSC:6990 Stock Report

Market Cap: HK$41.2b

Sichuan Kelun-Biotech Biopharmaceutical Future Growth

Future criteria checks 5/6

Sichuan Kelun-Biotech Biopharmaceutical is forecast to grow earnings and revenue by 2.6% and 23.9% per annum respectively. EPS is expected to grow by 6% per annum. Return on equity is forecast to be -1.2% in 3 years.

Key information

2.6%

Earnings growth rate

6.0%

EPS growth rate

Biotechs earnings growth42.2%
Revenue growth rate23.9%
Future return on equity-1.2%
Analyst coverage

Good

Last updated28 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

SHSC:6990 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262,615-214-1225717
12/31/20251,650-671-496-43917
12/31/20241,825-274-473-51217
6/30/20241,877-187-567-480N/A
3/31/20241,709-354-295-210N/A
12/31/20231,540-522-2360N/A
9/30/20231,523-427135207N/A
6/30/20231,505-333292355N/A
3/31/20231,155-440-942N/A
12/31/2022804-548-310-271N/A
12/31/202132-823-581-486N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6990 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: 6990 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 6990 is expected to become profitable in the next 3 years.

Revenue vs Market: 6990's revenue (23.9% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).

High Growth Revenue: 6990's revenue (23.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6990 is forecast to be unprofitable in 3 years.


Discover growth companies